Document Detail


Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
MedLine Citation:
PMID:  3315587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
25 patients with acute myocardial infarction pain lasting more than 20 minutes which was not relieved by nitrates, whose ECGs showed ST segment elevations of 1 mm or more in 2 or more ECG leads, and who presented less than 3 hours after onset of their symptoms were randomly assigned to one of 2 thrombolytic treatment groups: a single intravenous bolus of anisoylated plasminogen streptokinase activator complex (APSAC) 30U in 5 minutes or an intravenous infusion of streptokinase 1,500,000U over 60 minutes. 3 to 4 hours after the administration of the thrombolytic agent, all patients received intravenous heparin at full dosage for 24 hours. The patency of the infarct-related coronary vessels was assessed by angiography 1 to 4 hours after administration of the thrombolytic agent. Clinical signs, ECGs, pulse, blood pressure and temperature were monitored regularly for 24 hours after treatment or as clinically appropriate. APSAC seemed to be at least as effective as streptokinase in terms of patency of the infarct-related vessel (92% vs 63%, respectively). The adverse events were similar and none was life-threatening. APSAC and streptokinase caused similar falls in blood fibrinogen levels. APSAC, given as a bolus injection over 5 minutes, was easier to administer than streptokinase, which was given as an infusion during 60 minutes.
Authors:
P Monnier; U Sigwart; A Vincent; F Bachmann; J J Goy; M D Schaller; U Kaufmann; M Badan; M Grbic; C Perret
Related Documents :
9262627 - Magnesium deficiency and cardiogenic shock after cardiopulmonary bypass.
1351547 - Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the...
8498307 - Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive hea...
3871237 - Myocardial surgical revascularization after streptokinase treatment for acute myocardia...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  175-8     Citation Subset:  IM    
Affiliation:
Divisions de Cardiologie, Soins Intensifs et Hématologie, Lausanne.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anistreplase
Coronary Angiography
Female
Fibrinolytic Agents / therapeutic use*
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction / drug therapy*
Plasminogen / therapeutic use*
Random Allocation
Streptokinase / therapeutic use*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator com...
Next Document:  Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator compl...